Contents

Introduction 2
Key Contacts 3
Cardiovascular 4
Dermatology 6
Gastrointestinal 8
Infectious Disease 10
Inflammation & Immunity 12
Metabolism 14
Neuroscience 16
Oncology 18
Ophthalmology 20
Psychiatry 22
Respiratory 24
Stroke 26
Tissue 28
Women’s Health 30
Introduction

Scotland’s strengths in the life sciences and health care research are well proven. Much of this is underpinned by world-leading research conducted by our clinical academic research community within our National Health Service (NHS) and universities. This expertise, which spans a broad range of medical and disease research areas, is a vital component behind the translation of laboratory findings into real health-care benefits.

There continues to be investment in the infrastructure to enable the strengths of Scotland’s medical research expertise to be fully harnessed. This is evident through the Scottish Academic Health Sciences Collaboration (SAHSC) which builds on the close NHS and academic partnerships already existing in Scotland’s four university teaching hospitals – in Aberdeen, Dundee, Edinburgh and Glasgow – and through these to other Scottish Health Boards and universities. This collaboration - benefiting from a £15M investment in NHS research infrastructure - provides a fully integrated platform for world-class translational medicine research. This will enable even greater opportunities for industry, academia and our NHS to work in partnership.

Running in parallel to the SAHSC are the activities of NHS Research Scotland (NRS), involving key R&D Directors of the NHS and the Chief Scientist Office of the Scottish Government. Its work has focussed on streamlining and simplifying processes to enable efficient approval and contracting of clinical studies involving Scotland’s NHS. The introduction of the NRS Permissions Coordinating Centre (NRS Permissions CC), acting as a single point of contact for commercial and non-commercial multi-centre study approval has already seen impressive NHS R&D approval performance times.

Both the SAHSC and NRS are important initiatives helping to put Scotland at the forefront of translational medicine research. This Directory provides the biographies of a number of key clinical academic researchers within the SAHSC partner organisations, demonstrating a significant pool of talent across fourteen distinct areas of importance to translational medicine research. The Directory – on page 3 – also provides the details of key individuals who will help to facilitate opportunities for you to work with these researchers and to take full advantage of Scotland’s medical research capabilities.
Key Contacts

Dr Alison Walker
National Coordinator for the NRS Permissions Coordinating Centre

Through NRS Permissions CC Dr Alison Walker is responsible for overseeing the efficient coordination of R&D NHS management approval for both commercial and non-commercial multicentre research in Scotland. Within the Coordination Centre, Alison also has a key business development role of increasing the number of opportunities for commercial clinical studies involving NHSScotland, which are typically standard Phase I to IV studies sponsored and funded by industry. To facilitate this she has a key responsibility for promoting and coordinating opportunities between local, national and international investigators and commercial companies with an interest in clinical research.

Contact details
Tel: +44 1224 554 051
Mail: alisonwalker1@nhs.net

Dr Ross McLennan
Academic / Industry Collaboration Coordinator

Dr Ross McLennan has a key business development role and is responsible for fostering and coordinating collaborations between the SAHSC partner organisations and industry. Unlike conventional Phase I to IV studies that are coordinated through NRS Permissions CC and contracted through the NHS, Ross will support the development of national collaborations where SAHSC academic and industry partners will work together to provide their intellectual and developmental expertise to a collaboration, which may also be sponsored by one of the SAHSC academic partners. Ross’s role is to increase the science added opportunities available to meet the needs of industry. Ross leads in facilitating communication between staff of the SAHSC partners – including investigators, members of technology transfer and R&D offices – and industry with a view to establishing new and efficient collaborations.

Contact details
Tel: +44 141 330 2315
Mail: r.mclennan@tmri.co.uk

Dr Elizabeth Rattray
Deputy Director, Research & Innovation, University of Aberdeen

Dr Elizabeth Rattray has been Deputy Director within Research & Innovation at the University of Aberdeen since 2005 and has gained extensive experience of the technology transfer process both on a UK and international basis. Her experience includes licensing of technology, large scale industry collaborations and forming new companies from the university sector, all with a particular focus to life sciences and the pharmaceutical industry. Representing the 4 SAHSC partner universities, Elizabeth leads on the contracting for collaborative research opportunities between these universities and industry.

Contact details
Tel: +44 1224 274 369
Mail: e.rattray@abdn.ac.uk
Cardiovascular

Professor Anna Dominiczak OBE

Professor Anna Dominiczak is a British Heart Foundation Chair of Cardiovascular Medicine and heads the BHF Glasgow Cardiovascular Research Centre at the University of Glasgow. She is also a Consultant Physician and Endocrinologist at the Western Infirmary and Associate Dean for Research at the Faculty of Medicine.

She has a major research interest in cardiovascular genomics and systems medicine and holds a BHF Programme Grant. “Genomics and proteomics of hypertension and its vascular complications: the pathwayomic strategies.” Her total research income in the last 3 years is in excess of £35 million. She is a Fellow of the Royal College of Physicians, the Academy of Medical Sciences, the Royal Society of Edinburgh and the American Heart Association.

In addition to membership of several editorial boards, Professor Dominiczak was Editor-in-Chief of Clinical Science between 2004 and 2008. Her scientific and clinical contributions have been recognised by invitations to serve on the Medical Research Council Physiological Medicine Board, British Heart Foundation Project Grant Committee, the Wellcome Trust Physiological Science Committee and the Scientific Advisory Board of the Leducq Foundation. Professor Dominiczak is an author of 241 publications. In 2005 she was awarded OBE for services to medicine.

Professor Michael Frenneaux

He took up the Regius Chair of Medicine in Aberdeen in September 2009. He was previously BHF Chair of Cardiovascular Medicine at the University of Birmingham.

He qualified from Westminster Medical School in London in 1980 and was awarded the University of London Gold Medal.

After junior posts in medicine at the Hammersmith, Brompton and the National Hospital for Nervous Diseases Queen Square he trained in Cardiology, mainly at the Hammersmith Hospital. His research involves integrated ‘whole body’ physiology.

His research has focussed particularly on the pathophysiology of exercise limitation in hypertrophic cardiomyopathy and in systolic and diastolic heart failure, and on the role of cardiac energetic impairment in patients with heart muscle diseases and its correction by ‘metabolic modulators’. He has also shown that the apparent descending limb of the Starling mechanism in patients with heart failure is due to external constraint to the filling of the left ventricle by the pericardium and right ventricle and that this can be ameliorated by left ventricular pacing.

He is a Fellow of the Academy of Medical Sciences.
### Cardiovascular

**Professor Allan Struthers**

Allan Struthers is Professor of Cardiovascular Medicine. After graduating MB with Honours from Glasgow, he trained in Glasgow and London (Royal Postgraduate Medical School/Hammersmith Hospital) before becoming Wellcome Senior Lecturer in Dundee. He is currently funded as PI by the BHF, the MRC, the CSO, Diabetes (UK) and the Chest, Heart & Stroke Association. In total he has had 29 different BHF grants including two 5 year BHF awards (one as PI). One longstanding focus of interest has been B-type natriuretic peptide (BNP). He wrote one of the first two original papers published together in the Lancet which described the use of BNP to identify heart failure. More recently, his group has shown that BNP can identify silent myocardial ischaemia which opens up the possibility of using BNP screening to identify those individuals whose first ever manifestation of their heart disease is sudden unexpected death. This tantalising possibility is being investigated with a 5 year BHF special grant (the 5P study). He also pioneered the use of spironolactone in heart failure. He was the first to show its cardiac benefits in man in 1995 which led to the 1999 RALES study where it reduced cardiac death, for which it is now in widespread use. His other main focus is in xanthine oxidase inhibitors where he has shown that high dose allopurinol prolongs the time to ST depression during exercise in angina patients, making it a completely new antianginal drug. Another related focus is in using cardiac MRI to examine novel ways to regress left ventricular hypertrophy (LVH).

---

**Professor Dave Newby**

Professor Newby is currently British Heart Foundation Professor of Cardiology at the University of Edinburgh, Director of the Clinical Research Imaging Centre, Director of the Wellcome Trust Clinical Research Facility, Director of Research and Development for NHS Lothian and a Consultant Interventional Cardiologist at Royal Infirmary of Edinburgh. Professor Newby’s principal research interests are in endothelial and vascular biology, acute coronary syndromes and heart failure; focusing on clinical experimental and translational medicine. He has major imaging interests in atherosclerosis, abdominal aortic aneurysms and aortic valve disease using multidetector computed tomography, magnetic resonance imaging and positron emission tomography. Professor Newby has been involved in several multicentre trials including a major role in the conduct of the SALTIRE (Scottish Aortic stenosis Lipid lowering Trial, Impact on REgression). Professor Newby currently sits on the Editorial Board of the *Journal of the American College of Cardiology, Arteriosclerosis Thrombosis and Vascular Biology, Biochemical Pharmacology and Heart*. He is a member of the Project Grant Committee of the British Heart Foundation, and the Biomedical and Therapeutics Research Committee of the Chief Scientist’s Office at the Scottish Government. He currently sits on the UKCRN Experimental Medicine Advisory Group and Cardiovascular Speciality Subgroup.
Dermatology

**Professor Irene Leigh OBE**

Professor Irene Leigh is a graduate of the London Hospital Medical College and gained a Lecturership in medicine at the University of Dar es Salaam in Tanzania. In 1979 she returned to the UK and worked as a Senior Registrar at St John’s Hospital for Diseases of the Skin. Professor Leigh joined the London Hospital four years later as a Consultant Dermatologist, became a Senior Lecturer and then Professor of Dermatology in 1991. She was Director of the Cancer Research UK Skin Tumour Laboratory and Head of the Centre for Cutaneous Research at Bart’s and the London, Queen Mary’s School of Medicine and Dentistry from 1983 until 2006. In 1997 she was appointed Dean for Research, St Bartholomews and the Royal London School of Medicine and Dentistry. In 1999 she was awarded a DSc, became a Fellow of the Academy of Medical Sciences and became Professor of Cellular and Molecular Medicine. In 2002 she became Joint Director of Research and Development for Barts and the London Trust/School of Medicine and Dentistry. She was awarded an OBE in the 2006 Birthday Honours List for services to medicine, became a Fellow of the Royal Society of Edinburgh in 2009 and will be President of the Association of Physicians for UK and Ireland in 2010. In 2006, she became Head of the College of Medicine, Dentistry and Nursing at the University of Dundee and continues to research into skin cancer and genetic disease, in collaboration with an existing group led by Irwin McLean, and was instrumental in the move of the Cancer Research UK Skin Tumour Laboratory to Dundee.

**Professor Colin S Munro**

Professor Colin Munro is a Consultant Dermatologist at the South Glasgow University Hospitals Division of NHS Greater Glasgow providing services at the Southern General Hospital and the Victoria Infirmary in Glasgow. Professor Munro’s research interests include inherited disorders of keratinisation, such as ichthyoses, keratoderma and acantholytic genodermatoses. Professor Munro has an active collaboration with the Epithelial Genetics Group at the University of Dundee and is also a member of the European Geneskin consortium.
Dermatology

Professor Tony Ormerod

Professor Tony Ormerod has a wide range of active research interests in clinical and experimental dermatology. Disease areas of special interest include inflammatory dermatoses and therapeutic areas of medical dermatology notably psoriasis, eczema, occupational and contact dermatitis and pyoderma gangrenosum. Allied to this is an interest in the immunological basis of the inflammatory diseases and modification by novel therapy.

Specific interests are in adaptive immunity effector cells versus regulatory cells and tolerogenic conditions and how these impact on the expression of disease.

His research is patient orientated including studies of patient experience of care pathways for psoriasis, adherence to therapy, clinical trials and pharmacovigilance. This work aims to improve the evidence base to benefit important clinical questions and through guideline involvement to put research evidence into practice.

Professor Ormerod is Chief investigator in 2 major national studies that are currently ongoing. These are the BADBIR registry of biologic and conventional systemic interventions in the treatment of psoriasis. This aims to collect 5 year safety data and outcomes across several thousands of patients and is one of the premier disease registries in the field. The STOP-GAP trial is the first RCT to test in a large number of patients across the UK regarding the best initial therapy for this severe and serious, but rare condition and will also collect data for 5 years.

Professor Jonathan L Rees

Professor Rees graduated with honours from The University of Newcastle after having taken a first class honours in biostatistics. He trained in internal medicine in Newcastle and in Dermatology in Vienna, Strasbourg and Newcastle. He was Professor of Dermatology in Newcastle and moved to Edinburgh in 2000.

His major research contribution has been the elucidation of the genetics of sun sensitivity ('red hair gene'). In more recent years he has been interested in dermatological informatics, including automated and semi-automated diagnostic systems. He is the only UK clinician to be awarded the CERIES Research Award for dermatology, is a founder Fellow of the Academy of Medical Sciences, a past President of the European Society for Dermatological Research and has given the President’s Council Guest Lecture at Cold Spring Harbour Laboratory, the Darwin Lecture (University of Capetown), and the Rude Cormane Lecture of the European Society for Dermatological Research. He was awarded the David Anderson Berry medal of the Royal Society of Edinburgh for 2009 for his work on ultraviolet radiation and the skin.
Gastrointestinal

Dr John Dillon

Dr John Dillon is a Clinical senior lecturer in gastroenterology and Hepatology, and a principle Investigator in the Biomedical research Institute, Ninewells hospital and medical school, university of Dundee. He is also an honorary consultant with NHS Tayside.

Previously he graduated in Medicine from St Georges hospital medical school, University of London, and subsequently gained his MD based on research performed in the University of Edinburgh while a lecturer in Gastroenterology and Hepatology. He was an NHS consultant in Tayside, prior to his current appointment.

His current research interests are focussed on hepatic and oesophageal damage responses with a particular reference to oxidative stress, and biomarkers of these processes. He also performs record linkage studies on gastroenterological diseases.

Professor Emad El-Omar

Professor Emad El-Omar graduated MB ChB from Glasgow University in 1988 having obtained an intercalated BSc (Hons) degree in Pathology in 1986. He trained in General Medicine and Gastroenterology in Glasgow and gained dual accreditation in both in 1997. In 1995 he was awarded the degree of MD with honours and Belahouston Medal for his work on the effect of H. pylori infection on gastric acid secretion in man. In 1997, Professor El-Omar moved to the USA for further research opportunities. He spent 15 months in the Division of Infectious Diseases at Vanderbilt University School of Medicine, Nashville, Tennessee, and two years at the Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland. In July 2000, Professor El-Omar took up the newly created Chair of Gastroenterology at Aberdeen University. He was elected as a fellow of the Royal College of Physicians of Edinburgh in 2001, Association of Physicians of Great Britain & Ireland in 2001, and fellow of the Royal Society of Edinburgh in 2007. The main research thrust of the GI group is to understand the role of chronic inflammation in GI malignancy. Three novel research programmes have been set up around gastric cancer, colorectal cancer and inflammatory bowel disease. The common theme is the link between microbial-induced gastrointestinal inflammation and risk of malignant transformation. The main expertise is in molecular microbiology and molecular genetic research.
Professor Jack Satsangi
Professor Jack Satsangi is Professor of Gastroenterology at the University of Edinburgh. As a MRC Training Fellow and Clinician Scientist in the Nuffield Department of Medicine, University of Oxford, he was responsible for a series of important early observations in this field, notably the first genome-wide linkage scan in IBD.

Since his appointment in Edinburgh in 2000, he has developed an internationally competitive research programme in clinical as well as basic science aspects of IBD. He is a PI in the UK IBD Genetics Consortium and active member of international IBD collaborations in adult-onset and early-onset disease. He is secretary of the BSG IBD committee, SSG Research committee and represents Scotland in the UKCRN Speciality Group. He was co-chairman of the Working Party which developed the widely-used Montreal Classification system for phenotype assessment.

Professor Kenneth McColl
Professor McColl graduated in Glasgow in 1974 with Commendation. He was awarded an MD with Honours and the Bellahouston Medal in 1982. He spent one year in the University of California, San Francisco between 1982 and 1983 as part of an MRC Travelling Fellowship. He completed his General Medical and Specialist training in Gastroenterology in 1986 and was appointed Consultant General Physician and Gastroenterologist in 1987. He was appointed Professor of Gastroenterology in 1994.

Professor McColl leads an active research group. His initial research was into the acute porphyries and involved the studies of hepatic haem and bilirubin metabolism. He then developed an interest in the upper gastrointestinal tract disease. He became an expert on H. pylori infection and its role in the aetiology of duodenal ulcer disease and gastric cancer. This research involved studies of the mechanism by which H. pylori infection modifies a gastric physiology and, in particular, gastric acid secretion. He has also conducted a number of large-scale clinical studies investigating the effect of H. pylori infection on duodenal ulcer disease and non-ulcer dyspepsia as well as gastric cancer. More recently, the research group has focused on the aetiology of oesophageal adenocarcinoma and Barrett’s oesophagus. This has involved studies of luminal nitrite chemistry and also the mechanism by which gender influences the development of gastric and oesophageal cancer.
Infectious Disease

Professor Peter Davey

Peter Davey, MD FRCP, Professor in Pharmacoconomics and Consultant Infectious Diseases Physician, Quality, Safety and Informatics Research Group (Division of Community and Population Sciences and Education, University of Dundee. President of the British Society for Antimicrobial Chemotherapy, 2006-9.

Research interests: clinical epidemiology of infection and antimicrobial resistance, health technology assessment and quality improvement, particularly through the application of health informatics and record linkage of routine health services data. Research funding: European Union (Burden of Resistance and Disease in European Nations, Directorate General for Public Health and European Surveillance of Antimicrobial Consumption, European Centre for Disease Control); SHEFC Strategic Research Development Grant for Scottish Patient Safety Research Network; Chief Scientist Office. Key University of Dundee contributions to a UK Infection Capability Cluster: Health Informatics and record linkage of routine health services data (Scottish Health Informatics Platform); drug discovery of anti-parasitic and antibacterial drugs.

Professor David Goldberg

Professor Goldberg is a Consultant in Public Health Medicine/Consultant Clinical Epidemiologist at Health Protection Scotland (HPS) and is an Honorary Professor of Public Health, University of Glasgow. He is administrative head of HPS’s Group for Blood Borne Viruses, Sexually Transmitted Infections, Vaccine Preventable Diseases and Respiratory Infections and Lead on Hepatitis C and HIV programmes of work. He is a former Henry Mechan Professor of Public Health, University of Glasgow and Deputy Director of Health Protection Scotland. He serves on several UK and Scottish committees and is involved in the postgraduate supervision/teaching of students affiliated to the University of Glasgow. He is the author of approximately 170 peer-reviewed articles and a holder of many grants from a wide range of funding bodies. He, as Chair of Scotland’s Hepatitis C Action Plan Governance Board leads the coordination of Phase II of the Plan during 2008-11.
Infectious Disease

Professor Hamish McKenzie

His microbiological interests over the years have included work on urinary tract infection, immune responses in inflammatory bowel disease and the diagnosis of *Chlamydia trachomatis* infection.

The main theme of his more recent work has been to apply molecular techniques to the epidemiology of infection and in particular he has applied this to infection with *Moraxella catarrhalis* and *Streptococcus pneumoniae*. He has also studied the genetic basis of macrolide resistance in streptococci at the molecular level. Although his main professional role in recent years has become education, he retains a clinical role as an Honorary Consultant Microbiologist in a large diagnostic laboratory serving a population of around 570,000. Thus he is well placed to liaise at the interface between the everyday problems of infection and modern research approaches to these problems.

Professor Peter Simmonds

Peter Simmonds has been a Professor of Virology at Edinburgh University since 1995. His research interests are varied, but a common theme is in the evolution and epidemiology of virus infections, and interactions with their hosts. This has led to a variety of research investigations ranging from evolutionary studies of virus variability and recombination, molecular epidemiology and investigations of viral pathogenesis and interactions of virus with host cell defences. This has entailed the use and development of a variety of molecular biology laboratory methods, and a wide range of genetic and bioinformatic analysis techniques. In the HCV field specifically, his previous work has helped establish and implement the currently used HCV genotype nomenclature, and has been involved in several studies of the epidemiological and clinical significance of the virus’s genetic variability.

The discovery of large-scale RNA secondary structure in naturally persistent viruses including HCV is at the centre of an ongoing intensive research programme aimed at understanding more about RNA virus interactions with cell defence pathways and their evasion. He has trained in Clinical Virology, and contributes to the development of the virology diagnostic service at the Royal Infirmary of Edinburgh, undertaking a number of screening programs to evaluate the prevalence and clinical significance of newly discovered viruses, and evaluating the requirement and technology development for their diagnosis.
Inflammation & Immunity

Professor John Iredale

John Iredale is the Professor of Medicine at the University of Edinburgh. He divides his time between clinical practice in hepatology and research, as the leader of the Tissue Remodelling Group. Professor Iredale is also Director of the MRC/University of Edinburgh Centre for Inflammation Research based in the Queen’s Medical Research Institute, Little France. Previously Professor of Medicine and Director of Research at the University of Southampton, Professor Iredale built his career through a series of strategic career awards funded by the MRC, including Clinician Scientist and Senior Clinical Fellowships.

He has published extensively on the pathogenesis of hepatic and pancreatic fibrosis and has a number of current research interests which include defining the phenotype of the restorative versus the inflammatory macrophage during spontaneous resolution of liver fibrosis; using macrophages as vehicles to target the hepatic scar with therapies; determining the role of the desmoplastic reaction in oncogenesis and chemo resistance in primary and metastatic hepatological and gastrointestinal cancer. Professor Iredale is a Fellow of the Academy of Medical Sciences, is a member of the Wellcome Trust Molecules, Genes and Cells Grants Panel, and is an AMS/MRS Clinical Research Champion for Edinburgh and South East Scotland.

Professor Brian J. Lipworth

Professor Lipworth is head of the Asthma and Allergy Research Group, Professor of Allergy and Pulmonology at Ninewells Hospital and Medical School, University of Dundee, and previously Honorary Professor of Medical Sciences, University of St Andrews, Scotland. He is a fellow of the Royal College of Physicians of both London and Edinburgh, and the UK Association of Physicians. He is also regional advisor to the Royal College of Physicians of Edinburgh. He was elected Honorary fellow of the American College of Allergy, Asthma and Immunology for his outstanding contributions to the specialty. He was visiting Professor in 2008 to Harvard Medical School, Brigham and Women’s Hospital.

Professor Lipworth has authored over 300 peer-reviewed papers and has served on the editorial boards of international journals, such as Clinical and Experimental Allergy, British Journal of Clinical Pharmacology, Pulmonary Pharmacology and Therapeutics, Drug Safety, Chest and Thorax. He is currently a member of the Medical Research Council College of Experts, and is a current member of the ARIA guidelines committee. Research interests include biomarkers in asthma and COPD, therapeutics of asthma, allergic rhinitis and COPD, pharmacokinetics of inhaled drugs, and pharmacogenetics of asthma therapy. Professor Lipworth was awarded the GlaxoSmithKline medal for outstanding research from the British Pharmacological Society in 2000 and the British Association of Pharmaceutical Physicians prize for research from the British Pharmacological Society in 1991. He also received the Methven Prize for research from the Scottish Thoracic Society in 1987 and 1988. Professor Lipworth studied Medical Science at University of St Andrews and University of Manchester and completed his doctoral thesis in 1990 on airway β2-adrenoceptor regulation. Professor Lipworth has an active, clinical commitment in respiratory and rhinology medicine, with a special interest in airway allergy. He runs a problem asthma clinic and a unique combined medical/surgical rhinology tertiary referral clinic with his ENT colleagues for one stop assessment of upper and lower allergic airway disease.
Inflammation & Immunity

Professor Iain B McInnes

After training in Medicine and Immunology at the University of Glasgow and at the National Institutes of Health, USA, Iain McInnes was appointed to the post of Professor of Experimental Medicine in University of Glasgow in 2002. He is currently Head of Division of Immunology, Infection and Inflammation in the Faculty of Medicine and a Consultant Rheumatologist based in Glasgow Royal Infirmary.

His research interests focus on mechanisms of inflammatory synovitis in rheumatoid and psoriatic arthritis. To this end he leads a translational program encompassing basic cellular immunology through to clinical intervention in phase I and II trials. Recently these studies have been extended to include the role of inflammation in atherogenesis with an emphasis on co-morbidity in autoimmunity. His work has been recognised in award of many awards notably the Michael Mason Medal (BSR 2002), Albrecht Hasinger Lectureship (Berlin 2003) and recently the Nana Svartz Lectureship (Swedish Medical Society 2008). A past chair of the European League Against Rheumatism (EULAR) Scientific Committee, he is now Chair of the EULAR Committee for Clinical Affairs, and also serves on the MRC Panel for Training and Fellowships and as vice chair of the Arthritis Research Campaign Research Committee.

Professor David M Reid

He has held a personal chair in Rheumatology at the University of Aberdeen since 1999 and is Head of the Division of Applied Medicine at the School of Medicine & Dentistry. Graduating in Medicine from Aberdeen he undertook his initial clinical research on bone mass in rheumatic disease as an arthritis research campaign Lecturer in rheumatic disease at the University of Edinburgh. He has over 250 original papers and reviews, largely on his current research interests which include the utility of bone mass assessment, assessment of risk of fracture, treatment of secondary osteoporosis and the assessment of long-term disease activity and assessing risk of osteoarthritis. He is currently supervising 2 clinical PhD students and has successfully supervised 5 MD and 5 non-clinical PhD students in the past. He was head of the Bone and Musculoskeletal Research Programme at the University of Aberdeen from 2000-6 organising a full programme of translational medical research.

He is the Chairman of the Board of Trustees of the UK National Osteoporosis Society(NOS) having previously been chair of the Medical Board and their Research Grants Committee. He was a member of the Writing Groups for the Scottish Integrated Guidelines Network on the Management of Osteoporosis (publication in 2003) and Royal College of Physician’s Guidelines on Glucocorticoid-Induced Osteoporosis published in December 2002. Recently he chaired groups who have published the Arthritis and Musculoskeletal Alliance Standards of Care for Metabolic Bone Diseases and a UK expert group who have produced Guidance on the Management of Cancer Treatment Induced Bone Loss. He is currently President of the Scottish Society for Rheumatology.
Metabolism

Professor Andrew D Morris

Andrew Morris is the Professor of Diabetic Medicine and Director of the Biomedical Research Institute at the University of Dundee. He leads a translational research team that focuses on the epidemiological and molecular aetiological basis of diabetes and its complications. He also has a major interest in how managed clinical networks can improve patient care across geographical boundaries. He leads the DARTS research study, has published over 200 original papers and has attracted over £20million in peer reviewed grant funding.

He is the principal investigator on many clinical studies of new therapeutics of diabetes as well as genetics of diabetes, including the Wellcome Trust United Kingdom Case Control Collection for Type 2 Diabetes that has recruited 20,000 individuals. He is also the principal investigator of Generation Scotland, a study of the genetic health in up to 50,000 Scots. He was awarded the RD Lawrence Award by Diabetes UK in 2003, the Saltire Society Scottish Science Award in 2005 and is a Fellow of the Royal Society of Edinburgh, Scotland’s national academy of science and letters, and Fellow of the Academy of Medical Sciences. He was appointed by the Minister for Health and Community Care to be Lead Clinician for diabetes in Scotland (2002-2006) and led a national programme of quality improvement in diabetes care. He also chairs the Translational Medicine Research Collaboration Steering Group, a unique £50million collaboration between all Medical Schools in Scotland and the pharmaceutical company Pfizer.

Professor Donald Pearson

After undergraduate life in Biochemistry and Medicine in Glasgow, Donald completed his postgraduate training in Glasgow, Inverness and Aberdeen. He was appointed Consultant Physician/Diabetologist in Aberdeen in 1984. Until 2006 he was Lead Clinician for the Grampian Diabetes Managed Clinical Network and Head of Specialist Diabetes Services. He took up the position of Lead Clinician in Scotland and Chair of the Scottish Diabetes Group in August 2006. The Scottish Diabetes Group oversees the implementation of evidence based diabetes care as outlined in the Scottish Diabetes Framework and the Diabetes Action Plan. The group is multidisciplinary and, as well as health professionals, includes Scottish Government Health Department staff and patients.

Through its subgroups and in collaboration with regional networks it leads several initiatives to improve the lives of over 200,000 people with diabetes in Scotland. He has served on numerous local and national diabetes advisory bodies. Personal research interests include pregnancy (previous Chair of the Diabetic Pregnancy Study Group of the European Association for the Study of Diabetes) and diabetes in young people (recent Chairman of the Scottish Study Group for the Care of Diabetes in the Young). He is on the executive of the Scottish Diabetes Research Network.
Metabolism

Professor Naveed Sattar

Naveed Sattar graduated from Glasgow University in 1990 and was appointed Professor of Metabolic Medicine in 2005. He is interested in the causes, screening and prevention of heart disease, diabetes and obesity, and has considerable expertise in understanding the ‘links’ between different diseases. Such expertise allied to excellent resources for large scale work has attracted biomarker work on several internationally recognised cohorts and trials [e.g. WOSCOPS, PROSPER, BRHS, BWHHS, ASCOT, ALSPAC, Reykjavik, etc]. He also contributes to the Emerging Risk Factor Collaboration (ERFC) which has the potential to refine CVD risk prediction. Naveed also contributes increasingly to relevant trials in these areas, including UK-wide trials as well as work on end-point and data safety monitoring committees, and has accumulated related expertise in the area of rheumatoid arthritis and heart disease with several ongoing trials.

He has published over 200 original papers and over 20 chapters and has an H-index of 40. He has received several national awards for his research and been invited to present at numerous international conferences. He is chair of the conference organising committee for Diabetes UK 2010 annual meeting, and was recently recruited to the British Heart Foundation project grants committee. He also chaired the treatment subgroup for the Scottish Intercollegiate Guideline Network (SIGN) on obesity and contributes his expertise to other clinical guidelines. Finally, he is on the editorial board for Journal of Clinical Endocrinology & Metabolism and has recently taken up a role as an associate editor for Diabetologia, Europe’s premier diabetes journal.

Professor Jonathan Seckl

Jonathan Seckl is both medically and scientifically trained (MBBS at UCL, PhD in neuroendocrinology at Imperial College London). A clinical endocrinologist and former Wellcome Trust Senior Clinical Research Fellow, Seckl’s research focuses on glucocorticoid biology from ‘cloning to clinic’. The laboratory exploits technologies from molecular and cell biology through models in vivo to detailed clinical investigation. The main themes are the discovery and understanding of the importance of local tissue regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenases as a cause of and therapeutic target for age-related memory impairments and the metabolic syndrome-diabetes-obesity continuum. The group also advanced and supported the glucocorticoid hypothesis of fetal ‘programming’ and has elucidated mechanisms by which this leads to subsequent disorders in adult life. Seckl has authored over 280 peer-reviewed scientific papers (career citations ->16,000). He has given over 200 invited lectures at international meetings including many plenary talks. Prof Seckl led the new-build interdisciplinary Molecular Medicine Centre (130 researchers), set up the interdisciplinary Centre for the Study of the Ageing Brain (now an MRC Centre), has been head of the Department of Medical Sciences (180 staff), was inaugural Head of School of Molecular and Clinical Medicine (500 staff), and is now Director of Research for the College of Medicine and Veterinary Medicine. He has been on grant awarding committees for the MRC, Wellcome Trust, RSE, other UK charities and the EU and was a member of the Scottish Government’s Scientific Advisory Committee and an RAE2008 subpanel. He is currently on the MRC DPFS Panel and the council of the Academy of Medical Sciences.
Scottish Academic Health Sciences Collaboration  A World Leading Clinical Platform for Patient Orientated Research

Neuroscience

Dr Alison Murray

Dr Alison Murray is a Clinical Senior Lecturer in Radiology at the Aberdeen Biomedical Imaging Centre, University of Aberdeen. This houses the 3T research magnetic resonance imaging (MRI) scanner. Research MRI facilities are located within the acute NHS hospital, with research access to 1.5T MRI facilities, and are immediately adjacent to the John Mallard PET Centre and the NHS Department of Nuclear Medicine, facilitating combined studies of brain structure and function. Her research is in structural and functional brain imaging correlates of cognitive ageing and dementia and current work includes MRI in the Aberdeen 1936 Birth Cohort, and MRI, regional cerebral blood flow SPECT and FDG PET in clinical trials of novel Tau Aggregation Inhibitor therapies in Alzheimer’s disease. She is also involved in brain imaging research in neurodegenerative and neurodevelopmental diseases, utilising quantitative assessment of brain volumes, disease burden and function. She has extensive clinical experience of brain imaging in dementia, being responsible for over 500 nuclear medicine brain regional cerebral blood flow SPECT studies per annum, receptor studies in movement disorder and, with colleagues in Nuclear Medicine, development of a national clinical PET service across Scotland. She is Deputy Director of SINAPSE.

Professor Douglas Steele

In the ‘80s Professor Steele studied pure Physics at Strathclyde University obtaining a BSc hons, then went on to obtain a PhD in Physics at Glasgow University. Following this he worked as a Medical Physicist in Glasgow before moving to London as a Software Engineer for General Electric Ltd.

Soon afterwards he went back to University, this time to Edinburgh University, to study Medicine. He qualified MBChB in ’95 and went on to specialise clinically in Psychiatry obtaining MRCPsych and MD degrees. He specialises academically in neuroimaging studies of psychiatric disorders and has a particular interest in treatment resistant mood disorder. Over the past 4½ years he worked as a Senior Lecturer in Mental Health at Aberdeen University and as an Honorary Consultant Psychiatrist for NHS Grampian. In January 09 he moved to Dundee University as Professor of Neuroimaging and Honorary Consultant Psychiatrist for the Advanced Interventions Service, NHS National Services Scotland.
Professor Joanna M Wardlaw
Joanna Wardlaw has been Professor of Applied Neuroimaging at the University of Edinburgh since 2001 and Honorary Consultant Neuroradiologist with NHS Lothian. She graduated MB ChB (Hons) in 1982 with the Ettles Scholarship and Leslie Gold Medal for the most distinguished student of the year. Her training included general medicine and radiology (specialising in neuroradiology), and an MRC Research Training Fellowship. She has held posts in Glasgow (Institute of Neurological Sciences) as an NHS Consultant Neuroradiologist, and in Edinburgh as an MRC-funded Senior Lecturer in Neuroradiology. In 1996, she established the SFC Brain Imaging Research Centre housing a 1.5T research optimised MR scanner, providing imaging for research in stroke, ageing, psychosis, oncology, dementia and normal brain function. In 2007, with colleagues from six Universities, she established the SINAPSE collaboration, (Scottish Imaging Network, A Platform for Scientific Excellence) to enhance infrastructure for neuroimaging research across Scotland. She has published two books and over 260 original research papers covering her main research interests which include: acute ischaemic stroke pathophysiology, thrombolytic treatment for acute ischaemic stroke (she has maintained two Cochrane Reviews on thrombolysis in stroke since 1994, is on the steering committee and expert image review panels of several large international multicentre thrombolysis trials), the cause of cerebral microvascular disease - lacunar ischaemic stroke and white matter lesions – and role of the blood-brain barrier in ageing and vascular disease and systematic evaluation of diagnostic tests. Her research has changed clinical guidelines for stroke worldwide. In her NHS role, she co-ordinates neuro-imaging services for stroke in Lothian, many local improvements being based on the results of her research.

Professor Hugh Willison
Professor Hugh Willison is a Clinical Academic at the University of Glasgow and Honorary Consultant Neurologist with the South Glasgow University Hospitals. His research sits at the interface between immunology and glycobiology, with particular reference to antibody-mediated mechanisms of peripheral nerve disease. He combines his research with clinical activity on the diagnosis and management of patients with autoimmune peripheral nerve disorders, including Guillain Barré syndrome and chronic inflammatory neuropathies. He also directs a clinical diagnostic laboratory that conducts immunological tests of relevance to peripheral nerve disorders.

He undertook his research training at the National Institutes of Health, Bethesda USA, and his clinical training in Neurology at the Royal Free Hospital and National Hospital, London, and took up posts at Glasgow University and associated hospitals in 1990. His research laboratory is funded principally through The Wellcome Trust and he is the author of a wide range of articles on clinical and experimental aspects of peripheral nerve disease. He is a Fellow of the Royal Society of Edinburgh.
Oncology

Professor Jim Cassidy

Professor Jim Cassidy is a Cancer Research UK Professor of Oncology and Academic Head of the Centre for Oncology and Applied Pharmacology at the University of Glasgow. He is also Head of the University of Glasgow Division of Cancer Sciences and Molecular Pathology. He received his medical degree in 1981 and his Fellowship in Oncology in 1988 from the University of Glasgow.

Previously Professor of Oncology in Aberdeen he took up his present post in 2002. He runs a laboratory based programme of research and is Director of the Cancer Research UK Trials Unit. He has published over 170 peer-reviewed articles in scientific and medical journals, and contributed to several book chapters.

Professor David Harrison

Professor David Harrison is Professor and Head of Division of Pathology in the University of Edinburgh, Honorary Consultant Pathologist in Lothian University Hospitals Division and Director of the Breakthrough Research Unit, Edinburgh. He was Director of the Edinburgh Cancer Research Centre before its inclusion into the Institute of Genetics and Molecular Medicine, and he is now a Board member of the latter. He is a Fellow of the Royal College of Pathologists, the Royal College of Physicians of Edinburgh and the Royal College of Surgeons of Edinburgh. His research interests are in cell injury and death, and their genetic regulation, in health and disease.

In addition he is interested in computational systems biology, and how this nascent field can be applied meaningfully to breast cancer research. His other main area of interest is education, in particular using distance learning and blended learning for postgraduate training. He holds Adjunct Professorships in University of Florida, Gainesville and University of Canberra. He is a member of the Cancer Research UK Strategic Advisory Group and sits on several grant giving bodies. In his spare time he chairs a charity that owns and runs a hospital and nursing school in the Middle East.
Dr Russell Petty

Dr Russell Petty is a Clinical Senior Lecturer in Medical Oncology in the School of Medicine and Clinical Speciality lead for Oncology at the University of Aberdeen. He also practices as a Consultant Medical Oncologist in NHS Grampian. Following first class honours in General Pathology, he graduated MB ChB with commendation from the University of Dundee and completed general professional training in Ninewells Hospital Dundee, The Royal Hobart Hospital in Australia and in Newcastle General Hospital then specialist training in Medical Oncology at The Northern Centre for Cancer Treatment in Newcastle, Aberdeen Royal Infirmary and as a Fellow at Auckland City Hospital and the University of Auckland in New Zealand. As a clinical research fellow he completed his PhD in the Departments of Medicine and Therapeutics and Pathology at the University of Aberdeen, in the application of gene expression profiling in lung and rectal cancer to identify novel biomarkers and therapeutic targets. He was appointed to his current position in August 2007 and is the leader of the Medical and Experimental Oncology Group undertaking translational cancer research in the Section of Translational Medical Sciences. Dr Petty’s research interests are in translational cancer medicine, in particular novel therapeutic target and biomarker identification, clinical qualification, assay validation and agent development. He is interested in all aspects of clinical cancer biology and systemic cancer treatment with a particular focus upon oesophageal and gastric cancers. Research programmes combine clinical and preclinical investigation to focus on an improved biological classification of human tumours particularly in relation to important clinical phenotypes and clinical outcomes, to facilitate therapeutic and biomarker discovery and development.

Professor Alastair Thompson

Professor Alastair Thompson graduated from the University of Edinburgh with a BSc (Hons) and MBChB with Distinction in Surgery. He trained as a surgeon (Fellow of the Royal College of Surgeons of Edinburgh, FRCS(Ed)) and clinician scientist before joining the University of Dundee in 1996 where he is Professor of Surgical Oncology. He is also currently Director of the Clinical Research Centre in Dundee, Lead Cancer Clinician for the East of Scotland and Honorary Consultant Surgeon specializing in breast cancer at Tayside University Teaching Hospitals.

He leads a laboratory and clinical translational research program in Dundee with over £10 million funding since 2001, including linking the important p53 tumour suppressor network and mathematical modeling to clinical care in breast cancer. He actively contributes to drug discovery in Dundee and a range of phase I, II, III and IV clinical trials in the prevention, early detection and therapy of breast cancer. He is UK Chief Investigator or surgical lead on a range of innovative UK and international clinical trials. He chairs the London-based Breast Cancer Campaign Breast Tissue Bank Board for the UK and Eire. Based on experience with national audit for patient safety in surgery and oncology, he also works with the Health Informatics Centre in Dundee linking tumor and patient characteristics (e.g. adherence to cancer drugs) to clinical outcomes.

With numerous peer review publications, books and invited seminars at international meetings worldwide, his research has received awards including a King James IV Professorship in Surgery (Royal College of Surgeons of Edinburgh) the Richard Asher Prize (The Society of Authors and the Royal Society of Medicine) and a James IV Travelling Fellowship (James IV Association).
Professor Gordon Dutton

Professor Gordon Dutton is a Consultant Paediatric Ophthalmologist who also works at the Royal Hospital for Sick Children, Yorkhill, Glasgow and at the Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow. He obtained his undergraduate and initial postgraduate training in Bristol. His subsequent MD research into various aspects of toxoplastic retinochoroiditis was carried out in Glasgow.

He was a Senior Lecturer in ophthalmology for the University of Glasgow for seven years before taking up his current post. He has a wide range of interests in clinical ophthalmology which is reflected in his publication record. In recent years he has had a special interest in cerebral visual impairment due to brain damage in children.

Professor Bal Dhillon

Currently Consultant Ophthalmic Surgeon, Princess Alexandra Eye Pavilion, Edinburgh and Hon. Professor in Ophthalmology University of Edinburgh and Professor Visual Impairment Studies, Heriot Watt University, Edinburgh. I have published over 150 papers, 7 book chapters, a textbook, attracted research grants with wide experience in collaborative basic science and clinical research and supervised MD, PhD students and post-doctoral research fellows.

My research interests mirror my clinical activities in infectious diseases, age-related macular degeneration, visual impairment/rehabilitation, ocular regeneration, and imaging and retinal drug delivery. I am PI for a number of research projects and have experience in translating basic research into clinical useful interventions. I have led a number of initiatives in ophthalmology at regional and national levels, ranging from changes in the consultant contract, joint optometry shared care, single system working and integrating low vision services between primary and secondary care. For example, VisioncentrE3 combines service provision, rehabilitation and clinical research in partnership with social services, RNIB and University, and is widely cited as an exemplar multidisciplinary model attracting national awards and funding.
Ophthalmology

Professor John V Forrester

Professor Forrester received his MD, ChB from Glasgow University, Scotland in 1970. In 1980 he received his MD also from the University of Glasgow. Between 1979-1984 he was Consultant Ophthalmologist/Clinical Lecturer in Ophthalmology at Glasgow University. In 1984 he was appointed to his current post, Cockburn Professor of Ophthalmology University of Aberdeen/Honorary Consultant Ophthalmologist, NHS Grampian.

He has over the years received 16 awards and Visiting Professorships including the London Hospital Prize for Original Research in Ophthalmology in 1977, the Duke Elder Medal and the Ida Mann Medal in 1991. He received the Spinoza Professorship in Amsterdam in 1998 and the Kimura Lectureship as Visiting Professor (UCSF) University of California, San Francisco in 2004. His main areas of research are Diabetic Retinopathy, Angiogenesis, Endothelial Cell Function, Ocular Immunology, Uveitis, Autoimmune Disease, Imaging in Ophthalmology, Wound Healing and Corneal Transplantation and has published over 260 papers.

He is a Fellow of the Royal College of Surgeons of Edinburgh and Glasgow, Royal College of Ophthalmologists, Physicians of Edinburgh, Academy of Medical Sciences and the Royal Society of Edinburgh and recently became a Fellow of the Institute of Biology and the Association for Research in Vision and Ophthalmology. He is Chairman of the RCOphth Medical Ophthalmology Training Sub-Committee and the RCOphth Diabetic Retinopathy Guidelines Committee and a member of the MRC Advisory Board. He was previously Editor-in-Chief of the British Journal of Ophthalmology 1992-2000. He is currently an Editorial Board member of the British Journal of Ophthalmology, European Journal of Ophthalmology and Current Eye Research.

Professor Caroline MacEwen

Professor Caroline MacEwen MB ChB, MD, FRCS, FRCOphth, FFSEM is a Consultant Ophthalmologist at Ninewells Hospital, Dundee and Head of the Department of Ophthalmology at the University of Dundee. Her main research interest is in the field of clinical ophthalmology and she has published more that 100 papers and written and contributed to textbooks for both undergraduate students and medical practitioners. She has an interest post-graduate education and is Associate post-graduate Dean in the East of Scotland.
Psychiatry

Professor Sally-Ann Cooper

Professor Cooper graduated from the University of London in 1985 with a medical degree and first class honours degree in pharmacology, and in 1999 was appointed to the University of Glasgow’s foundation Chair of Intellectual Disabilities Psychiatry, and Honorary Consultant Psychiatrist within NHS Greater Glasgow and Clyde. She has been Head of the Division of Community Based Sciences since August 2006, which includes the Section of Psychological Medicine.

She leads a research group employing epidemiological and trial methodologies to understand causation and determine effective interventions for children and adults with mental ill-health and developmental disorders, whilst the Section’s research also focuses on recovery processes from depression, aetiology and treatment of sleep disorders, and cognitive rehabilitation.

Professor Stephen Lawrie

Prof. Stephen MacGregor Lawrie has a personal chair in Psychiatry & Neuro-Imaging and is a Honorary Consultant Psychiatrist at the Royal Edinburgh Hospital. He is also Director of the Scottish Mental Health Research Network and Co-chair of the Lothian Joint Formulary. Prof. Lawrie is primarily interested in using structural and functional brain imaging to distinguish patients with schizophrenia from their relatives, and from other patients with major psychiatric disorders such as bipolar disorder and autism; and, as a means to this end, is also involved in genetic and multi-centre imaging studies.

As a practising clinician, he is interested in potential clinical applications of brain imaging in psychosis and in the development of novel treatments such as cognitive enhancers that might enhance outcomes in patients with established psychoses and possibly even prevent the onset of psychosis in high risk populations. He has published about 200 scientific articles in peer-reviewed journals, co-authored/edited five books, is on the editorial board of four journals, and is a sentinel reader for the American College of Physicians ‘Evidence-Based Medicine’ Journal. He is also a member of the Medical Research Council College of Experts, and a regular reviewer for several medical journals (including JAMA, Lancet and BMJ) and grant-giving bodies (including MRC and Wellcome Trust).
Psychiatry

Professor Keith Matthews

My main research interests fall within the areas of behavioural neuroscience, experimental psychology and clinical studies of the pathogenesis and treatment of Major Depression, Obsessive Compulsive Disorder (OCD) and developmental disorders such as Attention Deficit Hyperactivity Disorder (ADHD). I am also interested in the biology of adverse early experience. Specifically, I am interested in the effects of altered early social environment and the impact on behavioural and neural development. Adverse early experience appears to confer heightened vulnerability to the development of depressive disorders and the elucidation of the underlying mechanisms of such vulnerability represents a major challenge to the basic and clinical neurosciences. Clinically, I lead the Scottish Advanced Interventions / Neurosurgery for Mental Disorder Service for patients with the most chronic and treatment refractory forms of depression and OCD.

In addition to studies based within this unique, national, multidisciplinary clinical service (in collaboration with Sam Eljamel and David Christmas), my principal research collaborations are with David Coghill, Sarah Seth and Helen Smith (Developmental Research Group), Brian Kidd and Alex Baldacchino (Addictions Research Group), Douglas Steele (Clinical Neuroimaging) and David Balfour (Behavioural Neuroscience).

Professor Ian Reid

Ian Reid is Professor of Mental Health at the University of Aberdeen, working in the division of applied health sciences. He graduated MB CHB BMedBiol from Aberdeen in 1983, and was appointed lecturer in mental health there in 1985. From 1987-1990, he was Wellcome Trust Research Fellow in pharmacology at the University of Edinburgh, and lecturer in psychiatry there until 1992 when he returned to Aberdeen as Senior Lecturer in Mental Health. He was appointed to the chair in psychiatry in Dundee at the age of 34 in 1995, before taking up his current post in 2003. His interests focus on mood disorder, and he has conducted molecular, physiological, epidemiological studies in the field.
Respiratory

Professor Graham Devereux

Professor of Respiratory Medicine at the University of Aberdeen and a Consultant in Adult Respiratory Medicine at Aberdeen Royal Infirmary. He was an undergraduate at Cambridge and then Oxford Universities and trained in respiratory medicine in Newcastle, Nottingham and Aberdeen. His clinical subspecialties include Cystic Fibrosis and Lung Cancer and he conducts translational research into both of these conditions. His MD research focused on asthma epidemiology whilst his PhD focused on laboratory based cellular immunology. His main research interest is the identification of antenatal and early life influences on the development of asthma/allergic disease and the immune system.

Professor Brian J. Lipworth

Professor Lipworth is head of the Asthma and Allergy Research Group, Professor of Allergy and Pulmonology at Ninewells Hospital and Medical School, University of Dundee, and previously Honorary Professor of Medical Sciences, University of St Andrews, Scotland. He is a fellow of the Royal College of Physicians of both London and Edinburgh, and the UK Association of Physicians. He is also regional advisor to the Royal College of Physicians of Edinburgh. He was elected Honorary fellow of the American College of Allergy, Asthma and Immunology for his outstanding contributions to the specialty. He was visiting Professor in 2008 to Harvard Medical School, Brigham and Women’s Hospital.

Professor Lipworth has authored over 300 peer-reviewed papers and has served on the editorial boards of international journals, such as Clinical and Experimental Allergy, British Journal of Clinical Pharmacology, Pulmonary Pharmacology and Therapeutics, Drug Safety, Chest and Thorax. He is currently a member of the ARIA guidelines committee. Research interests include biomarkers in asthma and COPD, therapeutics of asthma, allergic rhinitis and COPD, pharmacokinetics of inhaled drugs, and pharmacogenetics of asthma therapy. Professor Lipworth was awarded the GlaxoSmithKline medal for outstanding research from the British Pharmacological Society in 2000 and the British Association of Pharmaceutical Physicians prize for research from the British Pharmacological Society in 1991. He also received the Methven Prize for research from the Scottish Thoracic Society in 1987 and 1988. Professor Lipworth studied Medical Science at University of St Andrews and University of Manchester and completed his doctoral thesis in 1990 on airway D2-adrenoceptor regulation. Professor Lipworth has an active, clinical commitment in respiratory and rhinology medicine, with a special interest in airway allergy. He runs a problem asthma clinic and a unique combined medical/surgical rhinology tertiary referral clinic with his ENT colleagues for one stop assessment of upper and lower allergic airway disease.
Professor Neil C Thomson
Professor Neil Thomson is Professor of Respiratory Medicine at the University of Glasgow, Head of Respiratory Medicine within the Division of Immunology, Infection & Inflammation and Honorary Consultant at Gartnavel General Hospital, Glasgow. He graduated from the University of Glasgow and undertook postgraduate training in Glasgow, London and McMaster University, Canada. He is a former member of the Committee for Safety of Medicine and a former Chair of the Scientific Committee of the British Lung Foundation and of the National Asthma Campaign Therapy Working Group. He is a recipient of the Tenovus Margaret Maclellan Award for his contribution to the fields of respiratory disorders within Scotland. He has co-edited several textbooks on asthma and COPD and published over 150 peer-reviewed papers on airway diseases. His current research interests include corticosteroid insensitivity in smokers with asthma, biomarkers in asthma and COPD and assessment of novel treatments for severe asthma.

Professor William MacNee
Professor William MacNee is Professor of Respiratory and Environmental Medicine, University of Edinburgh and Honorary Consultant Physician, Lothian University NHS Trust. His research interests involve the study of aspects of the inflammation in patients with chronic obstructive pulmonary disease (COPD) and particularly the cell and molecular mechanisms of the balance between oxidants and antioxidants in the lungs. He has developed an interest in the processes by which the lungs deal with inhaled toxic substances, especially air pollutants.
Dr Alex Doney

Dr Alex Doney leads the Acute Stroke Programme in Ninewells Hospital where an 18 bedded Acute Stroke Unit manages patients with stroke from the population of Tayside (approximately 400,00 people) in conjunction with a smaller (4 beds) unit at Perth Royal Infirmary. The service works closely with the Stroke Studies Centre led by Dr Ron MacWalter which is engaged in various commercial trials together with trials supported through the Scottish Stroke Research Network.

With a strong background in molecular genetics of complex diseases Alex is engaged in a wide range of research investigating the contribution of genetics to both disease susceptibility, progression and response to therapy (pharmacogenetics). This activity is supported by his experience in medical informatics and record linkage and contribution to the development of very large and successful bio-collections in Tayside. Research in stroke pharmacoepidemiology is supported by the development of a unique inpatient Stroke Management System eSIST, led by Alex, for capturing information on all patients that pass through the Acute Stroke Unit together with the Tayside Stroke Cohort which has successfully linked a unique and extensive prescribing dataset to cerebrovascular events in Tayside.

Professor Kennedy R Lees

Kennedy Lees is Professor of Cerebrovascular Medicine at the University of Glasgow and has been Director of the Acute Stroke Unit in the Western Infirmary in Glasgow since it was established in 1990. His research interests include acute neuroprotection and thrombolysis for stroke, stroke trial design and secondary prevention, including the use of antihypertensive drugs and their effect on cerebral blood flow. He has extensive experience with translational medicine in relation to stroke treatment. Recent research has concerned choice of outcome measures for stroke trials, the training of investigators in their use – such as the Rankin training programme - and the optimal analysis approaches. Professor Lees has helped co-ordinate multicentre stroke trials including PROGRESS, ASSIST, MAST-E and CARESS, and acted as principal investigator for the GAIN-International, IMAGES and SAINT I trials. He leads the Virtual International Stroke Trial Archive (VISTA) group, chaired the SAINT and CHANT Trials’ Steering Committee, is a past chairman of the European Stroke Council and an executive member of the European Stroke Organisation. He has chaired data monitoring committees for several acute stroke trials including ICTUS, DIAS, ASSIST, mRECT trials and ECASS 3. His current grants include CSO funding for the CARS trial, MRC funding for VITATOPS and ENOS trials, and NIH funding with Johns Hopkins for the CLEAR-3 trial.
Dr Mary Joan Macleod

Dr Mary Joan Macleod MBChB PhD FRCP is a Clinical Senior Lecturer in Clinical Pharmacology at the University of Aberdeen. Her main clinical area is Stroke Medicine and she is the Clinical Lead for the Acute Stroke Unit in Aberdeen Royal Infirmary. She is an active contributor to the Scottish Stroke Research Network and Scottish Stroke Care Audit. Her research interests include stroke genetics and epigenetics, imaging and vascular biomarkers, telemedicine and stroke outcomes.

Professor Peter Sandercock

Professor Peter Sandercock is a clinical neurologist actively involved in acute stroke care at the Western General Hospital in Edinburgh. He was the principal investigator for the first International Stroke Trial (IST-1), the first ‘mega-trial’ in acute stroke, to evaluate antithrombotic treatment with aspirin, heparin, both or neither in 20,000 patients recruited from almost 500 hospitals in 37 countries world-wide. He is currently involved in the design, conduct or analysis of a number of trials in stroke treatment and prevention (CLOTS, ENOS, PAIS, SEARCH, ADVANCE, ASCEND, AAA, STICH-2, HPS-THRIVE, RELY). He is co-chief investigator of the third International Stroke Trial (IST-3) of thrombolytic therapy for acute ischaemic stroke which seeks to recruit 3000 patients from 400 hospitals worldwide by mid 2009 (1800 recruited to date, making it by far the world’s largest clinical trial of this treatment).

He is Co-ordinating Editor of the Cochrane Stroke Group, which publishes and updates systematic reviews of trials different interventions for the treatment, rehabilitation and secondary prevention of stroke. The Group has published over 100 reviews. With his colleague, Dr Malcolm Macleod he has also worked on systematic reviews of animal experimental data, to try and make the process of translation from bench to bedside more fruitful. Professor Sandercock is also Director of Edinburgh Neuroscience.
Tissue

Professor Frank Carey

Consultant pathologist and Honorary Professor NHS Tayside and University of Dundee. Graduated from University College Cork and trained in pathology in Edinburgh. My research interests are in colorectal cancer and particularly the use of biomarkers in prognostic studies in the context of Bowel Screening. I have been involved in Tissue Banking since 1997 and have recently taken over as clinical lead for the Tayside Tissue Bank. I am clinical lead for the Scottish Pathology Network (SPAN).

Professor Barry Gusterson

Professor Gusterson qualified in Medicine from St Bartholomew's hospital and did his PhD at the Ludwig Institute for Cancer Research (London University). He was appointed as a Consultant Histopathologist at The Royal Marsden Hospital and Professor of Histopathology at the Institute of Cancer Research in London, where he was Head of the Section of Molecular Pathology. In 2000 Professor Gusterson moved to Glasgow as Professor of Pathology. He subsequently was appointed as Associate Dean for Research and was Head of Cancer Sciences until 2007. He is currently Head of the Sections of Pathology and Gene Regulation and of Forensic Medicine and Science. Professor Gusterson proposed the Beatson Translational Research Centre (BTRC) and is Project Director to build the BTRC and Medical Advisor to the Fundraising Team. Whilst in Glasgow Professor Gusterson has worked very closely with GGC Health Board in a number of roles, the key changes that he has effected have been to establish the Glasgow Biorepository of which he is the Director, and as Chairman of a pan Glasgow Committee he initiated the pan Glasgow Histopathology build at the Southern General Hospital. Professor Gusterson has sat on a number of International and National Advisory Committees including those of the Scottish Executive/MRC/CRUK/NIH and has a successful research programme in Breast Cancer and Breast Biology. He has also been responsible for a number of translational research projects through his position as Director of Pathology and member of the Scientific Committee of the International Breast cancer Study Group. He has published over 250 original papers, mainly on Breast Cancer, Breast Biology, Head, Neck Cancer and Soft Tissue Sarcomas and is a member of the MRC Panel of Experts.
Tissue

Professor David Harrison

Professor David Harrison is Professor and Head of Division of Pathology in the University of Edinburgh, Honorary Consultant Pathologist in Lothian University Hospitals Division and Director of the Breakthrough Research Unit, Edinburgh. He was Director of the Edinburgh Cancer Research Centre before its inclusion into the Institute of Genetics and Molecular Medicine, and he is now a Board member of the latter. He is a Fellow of the Royal College of Pathologists, the Royal College of Physicians of Edinburgh and the Royal College of Surgeons of Edinburgh. His research interests are in cell injury and death, and their genetic regulation, in health and disease.

In addition he is interested in computational systems biology, and how this nascent field can be applied meaningfully to breast cancer research. His other main area of interest is education, in particular using distance learning and blended learning for postgraduate training. He holds Adjunct Professorships in University of Florida, Gainesville and University of Canberra. He is a member of the Cancer Research UK Strategic Advisory Group and sits on several grant giving bodies. In his spare time he chairs a charity that owns and runs a hospital and nursing school in the Middle East.

Professor Graeme I Murray

Professor Murray is Professor of Pathology and Clinical Speciality lead for Pathology at the University of Aberdeen. He is an Honorary Consultant Pathologist to NHS Grampian with specific diagnostic interests in gastro-intestinal and hepatobiliary pathology. He is a member of the biological sciences funding committee of Cancer Research UK and an Associate Editor of The Journal of Pathology. He is also a member of the North of Scotland Research Ethics Committee and a member of the scientific executive of Generation Scotland. He was previously a member of The Scottish Council of The Royal College of Pathologists.

Professor Murray has research interests in tumour biomarkers with a particular focus on cytochromes P450, mechanisms of tumour invasion and metastasis, mechanisms of anti-cancer drug resistance and biology of colorectal cancer.
Professor Siladitya Bhattacharya

Prof. Siladitya Bhattacharya MBBS, MD (University of Aberdeen), FRCOG is a Professor in Reproductive Medicine at the University of Aberdeen and an Honorary Consultant NHS Grampian. His current post is Head of Section of applied Clinical Sciences, Division of Applied Health Sciences, School of Medicine and Dentistry, University of Aberdeen. Research Interests: Health services research in reproductive health including randomised trials, epidemiology of reproductive failure and systematic reviews. Ongoing projects in infertility include randomized trials in infertility, systematic reviews, epidemiology of reproductive failure and patient preferences in fertility treatment. Other areas of interest include management of heavy menstrual disorders and the effects of alternative modes of delivery on reproductive outcome and long term health in women.

Professor Hilary OD Critchley

Hilary Critchley is Professor of Reproductive Medicine at the University of Edinburgh (UK) and has been a clinical Consultant in Obstetrics and Gynaecology at the Royal Infirmary, Edinburgh since 1993. Her University Personal Chair was awarded in 1999. She is a graduate of Manchester University and undertook her clinical professional training in Manchester and Edinburgh. Between 1991 and 1993 she spent two years, post-accreditation at Monash University, Melbourne, Australia in order to extend her research interests in endometrial biology. Her research studies have focused upon local uterine mechanisms involved in menstruation, implantation and interruption/loss of early pregnancy. Specifically her laboratory studies have studied the interactions between the endocrine and immune system within uterine tissues. Clinical areas of study include assessment and evaluation of abnormal uterine bleeding and novel imaging of the uterus. Collaborative clinical studies with Paediatric Oncology address the late effects of treatment of childhood cancer upon uterine and ovarian function. Her expertise in the field of endometrial biology and reproductive medicine is nationally and internationally recognised. Her research programme has been supported by the Medical Research Council; The Wellcome Trust; Wellbeing/RCOG UK; National Health Service Health Technology Assessment Programme (NHSHTA); Chief Scientist Office of the Scottish Government (CSO); US National Institutes for Child Health and Development (NIHCHD).

Testimony to her research contributions are over 160 peer-reviewed publications. In April 2009 elected to the Academy of Medical Sciences. She is current Coordinator of ESHRE (European Society for Human Reproduction and Embryology) Special Interest Group for endometrium and endometriosis (SIGEE, deputy coordinator 2007-2009) and is a past-Convenor of Study Groups for the Royal College of Obstetricians and Gynaecologists.
Women’s Health

**Professor Mary Ann Lumsden**

Professor Mary Ann Lumsden is Head of Section of Reproductive & Maternal Medicine and Head of Division of Developmental Medicine at University of Glasgow. She has been involved in research for twenty-five years with a particular interest in benign gynaecology, which spans menstrual problems and the menopause. She carried out a number of projects assessing vascular function and the impact of steroid hormones, as well as the aetiology and management of heavy menstrual bleeding including that related to uterine fibroids. She currently has projects ongoing in both these areas. She still is a practising gynaecologist and her clinical activities support this research.

As Chair of the Clinical Academic Trainees’ Committee in the Faculty of Medicine at the University of Glasgow and also the Higher Degrees Committee for the Faculty, she has an involvement in the training of Clinical Academics that covers all specialties. She also has considerable experience in developing and running taught courses that have research projects as a component, thus, having an overview of many different aspects of academia within the Faculty and the relevance of collaboration and consistency across all the specialities. She is also Director of the Reproductive Medicine Unit (a self-funding assisted conception unit run by the UoG) and took over as President of The British Menopause Society in August 2009.

**Dr Gary Mires**

Dr Gary Mires is Professor of Obstetrics and Undergraduate Teaching Dean in the School of Medicine, University of Dundee, and an Honorary Consultant Obstetrician at Ninewells Hospital and Medical School. A Dundee graduate he has had the privilege of spending his professional career in Tayside. He was awarded his MD in 1994 and is a Fellow of the Royal College of Obstetricians and Gynaecologists (RCOG) and a Fellow of the Higher Education Academy.

His clinical interest is high risk pregnancy particularly the management of multiple pregnancy and pregnancy complicated by diabetes. His research interests relate to both Obstetrics and Medical Education. The main theme of his Obstetric research is the small baby particularly the antecedents and consequences of being small at birth. In respect of Medical Education he has published on inter-professional education, assessment and approaches to teaching and learning. He is currently Director of e-learning at the RCOG and Editor in Chief of the RCOG distance learning programme StratOG.net. He is a member of University of Dundee Court and Senate.
The Scottish Academic Health Sciences Collaboration is a partnership between:

NHS Grampian
NHS Greater Glasgow and Clyde
NHS Lothian
NHS Tayside

UNIVERSITY OF ABERDEEN
UNIVERSITY OF DUNDEE
UNIVERSITY OF EDINBURGH
University of Glasgow

CHIEF SCIENTIST OFFICE
Scottish Enterprise

For further information, please contact:

NHS Research Scotland
Permissions Coordinating Centre
Research & Development Office
Forsterhill House Annexe
Forsterhill
Aberdeen
AB25 2ZB
Tel: +44 (0) 1224 552 690
Email: nhsg.nrspcc@nhs.net

Life Sciences SCOTLAND

SE/3005/Feb10